[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Jishuitan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":265},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,69,87,105,132,159,188,215,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100649883","robot-assisted-closed-reduction-and-internal-fixation-for-intertrochanteric-femoral-fractures-100649883",false,"NCT07738458","Robot-Assisted Closed Reduction and Internal Fixation for Intertrochanteric Femoral Fractures","Robot-Assisted Closed Reduction and Internal Fixation for Intertrochanteric Femoral Fractures: A Randomized Controlled Trial","Inclusion Criteria：\n\n* Age 18 to 80 years, inclusive.\n* Male or female participants.\n* Acute, closed intertrochanteric femoral fracture.\n* AO\u002FOTA classification 31-A intertrochanteric femoral fracture.\n* Fracture requiring closed reduction and proximal femoral intramedullary nailing.\n* Injury-to-surgery interval no more than 14 days.\n* Participant or legally authorized representative is fully informed about the study.\n* Written informed consent voluntarily provided by the participant or legally authorized representative.\n\nExclusion Criteria：\n\n* Open fracture.\n* Pathological fracture.\n* Old fracture with an injury-to-surgery interval greater than 14 days.\n* Multiple fractures.\n* Previous surgery involving the affected hip joint.\n* Deformity of the affected hip joint.\n* Severe osteoarthritis of the affected hip joint.\n* Significant neuromuscular disease affecting lower limb function.\n* Significant neuromuscular disease affecting postoperative rehabilitation.\n* Severe systemic comorbidity that makes the participant unable to tolerate anesthesia or surgery.\n* Severe organ dysfunction that makes the participant unable to tolerate anesthesia or surgery.\n* Pregnancy.\n* Lactation.\n* Cognitive impairment that prevents compliance with postoperative follow-up or rehabilitation protocols.\n* Active psychiatric illness that prevents compliance with postoperative follow-up or rehabilitation protocols.\n* Other condition that prevents compliance with postoperative follow-up or rehabilitation protocols.\n* Current participation in another clinical trial that may interfere with evaluation of this study's outcomes.","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the clinical effectiveness and safety of robot-assisted autonomous closed reduction versus traditional manual closed reduction in adult patients aged 18 to 80 years with acute, closed intertrochanteric femoral fractures (Arbeitsgemeinschaft für Osteosynthesefragen\u002FOrthopaedic Trauma Association \\[AO\u002FOTA\\] classification 31-A). The main question it aims to answer is:\n\nWhether robot-assisted autonomous closed reduction can achieve a significantly higher rate of excellent and good bone fracture reduction compared to traditional manual reduction, as rigorously evaluated by low-dose computed tomography (CT) and a three-dimensional (3D) quantitative standard.\n\nResearchers will compare the robot-assisted autonomous closed reduction group (intervention group) to the traditional manual closed reduction group (control group) to see if the robotic system significantly improves 3D anatomical reduction precision, reduces intraoperative fluoroscopy times and radiation doses, shortens operation times, and ultimately enhances long-term clinical hip functions and health-related quality of life.\n\nParticipants will be asked to do the following tasks:\n\nComplete baseline medical screening, standard hip X-rays, and bilateral full-length thin-layer CT scans before the surgery.\n\nUndergo a 1:1 randomized allocation after anesthesia to receive either robot-assisted autonomous closed reduction or traditional experience-based manual closed reduction, both followed by conventional proximal femoral intramedullary nailing internal fixation.\n\nReceive post-operative low-dose CT scans before discharge or within 2 weeks after surgery to evaluate the fracture reduction quality.\n\nFollow a standardized Enhanced Recovery After Surgery (ERAS) rehabilitation pathway and attend scheduled follow-up visits at 1, 3, and 6 months after the surgery to monitor bone healing, hip functions, and quality of life",[27,28,29],"Intertrochanteric Fractures","Intertrochanteric Fractures of the Hip","Intertrochanteric Fractures of the Femur","RECRUITING","2026-07-28",{"date":33,"type":34},"2026-07-31","ACTUAL",{"date":36,"type":34},"2026-07-01",{"date":38,"type":21},"2028-12-29",{"name":40,"class":41},"Beijing Jishuitan Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100649862","robot-assisted-closed-reduction-and-internal-fixation-for-distal-femoral-fractures-100649862","NCT07738406","Robot-Assisted Closed Reduction and Internal Fixation for Distal Femoral Fractures","Key Technology Research and Development for Intelligent Minimally Invasive Precision Treatment of Fractures (Sub-project 3: A Randomized Controlled Trial of Robot-Assisted Closed Reduction and Internal Fixation for Supracondylar Femoral Fractures)","Inclusion Criteria:\n\n* Age between 18 and 80 years old\n* Unilateral, acute, closed extra-articular supracondylar femoral fracture (Arbeitsgemeinschaft für Osteosynthesefragen\u002FOrthopaedic Trauma Association AO\u002FOTA 33-A)\n* Time from injury to surgery ≤21 days\n* Able to walk independently before injury (assistive devices allowed)\n\nExclusion Criteria:\n\n* Open fractures or multiple severe traumas requiring priority treatment\n* Asymmetrical lower extremities, or prior malunion of the ipsilateral femur, or pre-existing deformities significantly affecting rotation\u002Flength evaluation\n* Unilateral fractures combined with other sites\n* Pathological fractures (tumor or metabolic)\n* Prior complex implants in place or previous surgeries significantly affecting evaluation\n* Active infection or severe systemic medical contraindications (unable to tolerate anesthesia\u002Fsurgery)\n* Cognitive impairment, poor compliance, pregnancy, or lactation\n* Deemed unsuitable by the investigator (e.g., unable to follow up, or extreme obesity severely limiting the surgical or robotic workspace)\n* Refused randomization or enrollment",{"count":51,"type":21},80,[24],"This study aims to evaluate the clinical efficacy and safety of an intelligent robotic system for the closed reduction of extra-articular supracondylar femoral fractures (Arbeitsgemeinschaft für Osteosynthesefragen\u002FOrthopaedic Trauma Association AO\u002FOTA 33-A). Traditional manual reduction for supracondylar femoral fractures is often challenging due to strong muscle pull, heavily relying on the surgeon's experience and frequently requiring repeated fluoroscopy. This clinical trial compares robot-assisted closed reduction against traditional surgeon-led reduction methods. The primary goal is to determine if the robotic system improves the precision of bone alignment (excellent and good reduction rate) and functional recovery while reducing surgical radiation exposure.",[55,56],"Supracondylar Femoral Fractures","Femoral Fractures",[58,59,60,61,62],"Fracture Fixation","Robotic Surgical Procedures","Minimally Invasive Surgical Procedures","Anatomic Reduction Standard","Artificial Intelligence",{"date":33,"type":34},{"date":36,"type":34},{"date":66,"type":21},"2028-12-31",{"name":40,"class":41},2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":86,"locationsCount":42},"100649807","robot-assisted-closed-reduction-and-internal-fixation-for-femoral-shaft-fractures-100649807","NCT07738380","Robot-Assisted Closed Reduction and Internal Fixation for Femoral Shaft Fractures","Robot-Assisted Versus Traditional Closed Reduction and Internal Fixation for Femoral Shaft Fractures: A Randomized Controlled Trial","Inclusion Criteria：\n\n* Age 18 to 80 years, inclusive.\n* Unilateral, acute, closed femoral shaft fracture.\n* AO\u002FOTA classification 32-A, 32-B, or 32-C femoral shaft fracture.\n* Time from injury to surgery no more than 21 days.\n* Ability to walk independently before injury, with or without assistive devices.\n* Ability to provide written informed consent.\n\nExclusion Criteria：\n\n* Open fracture.\n* Multiple severe trauma requiring immediate priority management.\n* Asymmetry of the lower limbs.\n* History of ipsilateral femoral shaft malunion.\n* History of ipsilateral femoral deformity that significantly affects assessment of - limb rotation or length.\n* Ipsilateral fracture at another site.\n* Pathological fracture caused by tumor, metabolic bone disease, or other underlying bone pathology.\n* Complex hardware from previous ipsilateral surgery.\n* History of ipsilateral surgery that significantly affects clinical or radiographic evaluation.\n* Active infection.\n* Severe underlying medical condition that makes the patient unable to tolerate surgery.\n* Cognitive impairment that prevents study participation or follow-up.\n* Poor compliance with study procedures or follow-up.\n* Pregnancy or lactation.\n* Judged by the investigators to be unsuitable for enrollment.\n* Unable to complete the planned follow-up period.\n* Refusal to undergo randomization.\n* Refusal to participate in the clinical study.",{"count":51,"type":21},[24],"The goal of this clinical trial is to evaluate the safety and efficacy of robot-assisted closed reduction for patients with femoral shaft fractures. The main questions it aims to answer are:\n\nDoes robot-assisted closed reduction provide a statistically significant improvement in the excellent and good reduction rates compared to conventional surgeon-performed reduction? How do the two reduction methods compare in terms of surgical efficiency, fracture healing, and patient functional outcomes? Researchers will compare the robot-assisted closed reduction group to the conventional surgeon-performed reduction group to see if robot-assisted surgery improves the precision of fracture reduction, stability of alignment, and post-operative functional recovery while minimizing trauma.\n\nParticipants will:\n\nUndergo standardized screening to ensure they meet the inclusion criteria for acute, unilateral, closed femoral shaft fractures (Arbeitsgemeinschaft für Osteosynthesefragen\u002FOrthopaedic Trauma Association \\[AO\u002FOTA\\] classification 32).\n\nBe randomized in a 1:1 ratio to receive either robot-assisted closed reduction or traditional surgeon-performed closed reduction, both followed by internal fixation.\n\nComplete standardized perioperative management and follow-up assessments at 1, 3, 6, and 12 months post-surgery, including functional scales such as the Lower Extremity Functional Scale (LEFS) and the EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L), as well as radiographic imaging to monitor bone healing and potential complications.",[80,81,82],"Femoral Shaft Fractures","Femur Fractures","Femur Fracture",{"date":33,"type":34},{"date":36,"type":34},{"date":38,"type":21},{"name":40,"class":41},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":104,"locationsCount":68},"100649478","robot-assisted-closed-reduction-and-internal-fixation-for-extra-articular-distal-tibial-fractures-100649478","NCT07733271","Robot-Assisted Closed Reduction and Internal Fixation for Extra-Articular Distal Tibial Fractures","Key Technology Research and Development for Intelligent Minimally Invasive Precision Treatment of Fractures (Sub-project 4: A Randomized Controlled Trial of Robot-Assisted Closed Reduction and Internal Fixation for Distal Tibial Fractures)","Inclusion Criteria:\n\n* Unilateral, acute, closed distal tibial fractures (Arbeitsgemeinschaft für Osteosynthesefragen\u002FOrthopaedic Trauma Association AO\u002FOTA 43-A)\n* Time from injury to surgery \\\u003C 21 days\n* Able to walk independently before injury (assistive devices allowed)\n\nExclusion Criteria:\n\n* Open fractures or multiple severe traumas requiring priority treatment\n* Asymmetrical lower extremities, or prior malunion of the ipsilateral tibia, or pre-existing deformities significantly affecting rotation\u002Flength evaluation\n* Ipsilateral fractures combined with other sites\n* Pathological fractures (tumor\u002Fmetabolic)\n* Prior complex implants in place or previous surgeries significantly affecting evaluation\n* Active infection or severe systemic medical contraindications (unable to tolerate anesthesia\u002Fsurgery)\n* Cognitive impairment, poor compliance, pregnancy, or lactation\n* Poor local skin conditions (e.g., obvious blisters, severe soft tissue injury)\n* Deemed unsuitable by the investigator (e.g., unable to follow up as planned) or refused randomization\u002Fenrollment",{"count":20,"type":21},[24],"This study aims to evaluate the clinical efficacy and safety of an intelligent fracture reduction robot system in treating extra-articular distal tibial fractures. Traditional manual bone setting depends heavily on a surgeon's experience, which can sometimes lead to inconsistent alignment and increased radiation exposure. This clinical trial compares robot-assisted closed reduction against the traditional surgeon-led method. The primary goal is to determine if the robotic system improves the rate of accurate fracture alignment (excellent and good reduction rate) and helps patients recover better.",[98,99],"Distal Tibial Fracture","Tibial Fractures",{"date":101,"type":34},"2026-07-29",{"date":36,"type":34},{"date":66,"type":21},{"name":40,"class":41},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":42},"100616899","a-study-on-the-effectiveness-of-preventive-extensive-release-of-the-rotator-interval-and-joint-capsule-to-reduce-postoperative-stiffness-in-arthroscopic-rotator-cuff-repair-100616899","NCT07311616","A Study on the Effectiveness of Preventive Extensive Release of the Rotator Interval and Joint Capsule to Reduce Postoperative Stiffness in Arthroscopic Rotator Cuff Repair","Inclusion Criteria:\n\n1. Medium to small-sized (tear size \\\u003C3 cm) full-thickness supraspinatus muscle tears\n2. There was no shoulder joint stiffness before the operation. The range of motion of the joint was at least 160° for passive forward flexion under ROM anesthesia, 60° for external rotation when abduction was 0°, and equal to or greater than 60° for passive internal rotation at the level of the 10th thoracic vertebra\n3. About to undergo ARCR\n4. No history of trauma\n5. Patient consent to participate\n\nExclusion Criteria:\n\n1. There was a history of previous surgery on the ipsilateral shoulder\n2. Other injuries or lesions of the ipsilateral shoulder (such as glenohumeral arthritis, combined acromioclavicular joint dislocation, brachial plexus injury, etc.)\n3. It can not be completely repaired or even repaired during operation\n4. Have uncontrolled epilepsy or psychological illness\n5. Patients who were assessed as not suitable for inclusion in the study group",{"count":112,"type":21},50,[24],"The incidence of rotator cuff injuries is high, especially among the elderly. With the aging of the population, the number of surgical patients has increased significantly. However, in the early stage after arthroscopic rotator cuff repair, a considerable proportion of patients are troubled by shoulder joint stiffness, which greatly affects the quality of life and satisfaction of patients after the operation. Despite this, there is still a lack of clear evidence-based medical evidence regarding whether preventive extensive shoulder release and joint capsule release during arthroscopic rotator cuff repair can effectively prevent or alleviate postoperative shoulder stiffness. To clarify this clinical issue, this project intends to conduct a single-blind randomized controlled trial (RCT). Before the operation, patients will be randomly divided into two groups under blinding conditions: the experimental group will receive arthroscopic rotator cuff repair surgery along with preventive extensive shoulder joint release and joint capsule release, while the control group will only receive arthroscopic rotator cuff repair surgery. After the operation, the investigators will conduct follow-up visits for 3 months, 6 months and 12 months for the two groups of patients, and perform magnetic resonance imaging (MRI) at the 12th month to assess the healing of the rotator cuff tendons. ASES score, Constant-Murley score, Visual Analogue Scale (VAS) pain score and active range (ROM) assessment were conducted before the operation and at the follow-up at 3 months, 6 months and 12 months after the operation. The occurrence of postoperative complications of the patients was counted at the last follow-up. Through this study, the investigators expect to provide scientific and effective guidance for the prevention of postoperative adhesions of the shoulder joint.",[116],"Supraspinatus Tear",[118,119,120,121,122],"Rotator cuff repair","Postoperative stiffness","Joint capsule release","Randomized controlled trial","Range of motion of the shoulder joint","NOT_YET_RECRUITING","2025-12-16",{"date":126,"type":34},"2025-12-31",{"date":128,"type":21},"2025-12-22",{"date":130,"type":21},"2027-12-01",{"name":40,"class":41},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":42},"100604467","phase-3-a-study-of-collagen-scaffold-for-the-repair-of-elbow-cartilage-injury-100604467","NCT07149896","A Study of Collagen Scaffold for the Repair of Elbow Cartilage Injury","A Prospective Randomized Controlled Study Of Collagen Scaffold For The Repair Of Elbow Cartilage Injury","Inclusion Criteria:\n\n1. Subjects are between the ages of 18 and 55 (including 18 and 55 years old);\n2. Articular cartilage defect reaches Outerbridge grade III\u002FIV;\n3. The area of cartilage defect in a single site is 0.5cm²-2cm²;\n4. BMI 18≤BMI≤30;\n5. Clinically diagnosed cartilage defect requiring arthroscopic microfracture;\n6. Have not participated in other clinical trials within 3 months;\n7. Conservative treatment such as rest\u002Ftopical\u002Foral non-steroidal anti-inflammatory drugs for more than 3 months has not been effective\n8. Subjects fully understand the benefits and risks of this trial, are willing to participate and sign the informed consent form, and are able to cooperate with clinical follow-up.\n\nExclusion Criteria:\n\n1. Obvious narrowing of the elbow joint space or bone ankylosis formed between joints;\n2. Severe subchondral bone injury that cannot be undergoing microfracture surgery;\n3. Those with severe elbow deformity or systemic osteoarticular diseases;\n4. Secondary elbow arthritis with psoriasis, syphilitic neuropathy, brown yellow disease, metabolic bone disease;\n5. Elbow joint cartilage damage caused by joint fractures, infections, tumors, and immune diseases;\n6. Elbow joint tumors, rheumatoid, tuberculosis, suppuration and complications affecting the joint structure;\n7. Those who have undergone cartilage defect transplantation from bone marrow mesenchymal stem cell transplantation or other cartilage regeneration surgery within 12 months before surgery;\n8. Allergies, such as porcine protein allergy, past history or family history of autoimmune diseases;\n9. Those who regularly use sedatives, sleeping pills, tranquilizers or other addictive drugs;\n10. Combined with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases, mental illness;\n11. Those who cannot receive long-term and complex rehabilitation training after surgery;\n12. Women who are planning to have children, breastfeeding and pregnant women within 12 months;\n13. Those who have contraindications to MRI examination;\n14. Those who have special beliefs and cannot accept it (the product source is pig source);\n15. Those who are not suitable for inclusion by other researchers, such as those who cannot be judged for efficacy.","55 Years",{"count":141,"type":21},90,[143],"PHASE3","The goal of this clinical trial is to test whether adding a collagen protein scaffold can improve cartilage repair in elbow joint injuries, compared to standard surgery alone. The study will enroll 90 patients (aged 18-55) with elbow cartilage damage who haven't responded to conservative treatments.\n\nThe main questions it aims to answer are:\n\n* Does the collagen scaffold help regenerate better-quality cartilage (measured by MRI scans at 3 and 6 months)?\n* Do patients experience better pain relief and elbow function after this combined treatment?\n\nResearchers will compare two groups:\n\n* Experimental group : Receives microfracture surgery + collagen scaffold implant\n* Active Comparator group : Receives microfracture surgery alone\n\nParticipants will:\n\n* Undergo arthroscopic surgery (either procedure)\n* Complete follow-up visits at 1 week, 1 month, 3 months, and 6 months\n* Have MRI scans and functional assessments\n* Report pain levels and daily activity limitations through questionnaires",[146,147],"Cartilage Defect","Elbow Injury",[149,150],"elbow cartilage defect","collagen scaffold","2025-08-24",{"date":153,"type":34},"2025-09-02",{"date":155,"type":21},"2025-08",{"date":157,"type":21},"2026-12",{"name":40,"class":41},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100339417","china-health-big-data-100339417","NCT03699228","China Health Big Data","China Nationwide Multi Center Big Data Study on the Quantitative Computed Tomography (QCT) and Health Status of Check -up Population","China biobank","Inclusion Criteria:\n\nhealth check subjects 30-90 years old low dose chest CT scan\n\nExclusion Criteria:\n\npregnant women metal implant in the CT scan area","30 Years","90 Years",{"count":170,"type":21},30000,"OBSERVATIONAL","In this nationwide multi center study the investigators combine the low dose chest CT scan data with QCT technology, to measure the BMD of spine, VAT and liver fat in the health check subjects. The aim of this study is to evaluate the performance of QCT in the health check field, and further to evaluate the prevalence of osteoporosis, obesity and liver steatosis in health check population across China.",[174,175,176],"Osteoporosis","Obesity","Liver Steatoses",[178],"Bone mineral density, quantitative computed tomography, Osteoporosis, obesity, liver steatosis","2025-08-13",{"date":181,"type":34},"2025-08-17",{"date":183,"type":34},"2017-12-01",{"date":185,"type":21},"2026-12-31",{"name":40,"class":41},6,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":196,"sex":16,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":42},"100321161","chinese-second-hip-fracture-evaluation-100321161","NCT03461237","Chinese Second Hip Fracture Evaluation","Second Hip Fracture Evaluation in Chinese Elderly Patients Using Quantitative Computed Tomography","CSHFE","Inclusion Criteria:\n\n* a:Osteoporotic patients b:Osteoporotic hip fracture patients (femoral neck fracture and femoral trochanteric fracture) c: Be willing to and be able to join in the study and sighed the informed consent\n\nExclusion Criteria:\n\n* a:Under 47years old b:Non-surgical repair of hip fracture c:Pathologic fracture d:Violence-related trauma e:Bilateral hip implants or have hip replacement on the non-fractured side",true,"50 Years","95 Years",{"count":200,"type":21},3000,"1. To Compare overall rates of second hip fractures in both genders,\n2. To determine the effect of hip fracture on proximal femoral volumetric bone mineral density (vBMD), bone structure and muscle by quantitative computed tomography(QCT),\n3. To evaluate the contribution of QCT-image analysis to the prediction of the second hip fracture risk.\n4. To identify the differences between femoral neck fracture and trochanter fracture following hip fracture",[203,174],"Hip Fractures",[205,206,207,208],"Second Hip Fracture","Quantitative Computed Tomography","Bone structure","Muscle",{"date":181,"type":34},{"date":211,"type":34},"2017-05-01",{"date":213,"type":21},"2026-11",{"name":40,"class":41},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":42},"100583108","the-efficacy-and-safety-of-venostan-in-promoting-postoperative-swelling-reduction-in-patients-with-ankle-fractures-100583108","NCT06872034","The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures","The Efficacy and Safety of Venostan (Horse Chestnut Seed Extract Tablets) in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures: A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n* ≥18 year old, no gender restriction;\n* Diagnosed with ankle fracture confirmed by imaging data, AO classification: ---AO-43, AO-44-F3, AO-44;\n* Scheduled to undergo open reduction and internal fixation surgery;\n* Voluntary signing of the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* With contraindications to surgery;\n* With other severe combined injuries or soft tissue infections;\n* Severe multiple trauma: Injury Severity Score (ISS) \\> 16;\n* With concurrent fractures of the spine, pelvis, or ipsilateral or contralateral lower limbs;\n* Pathological fractures;\n* With peripheral vascular disease or deep vein thrombosis (DVT);\n* With severe impairment of heart, lung, liver, or kidney function or abnormal coagulation function;\n* Unable to walk independently before the injury;\n* With pre-existing lower limb edema (e.g., due to liver cirrhosis, kidney disease, etc.) before the injury;\n* With mental disorders or hyperalgesia;\n* Allergic to any component of the investigational drug;\n* Any contraindications that limit clinical evaluation and treatment of the patient;\n* Deemed unsuitable for inclusion in this study by the investigator.",{"count":223,"type":21},290,[24],"This study is a multicenter, open-label, randomized controlled trial planned to enroll patients with ankle fractures who meet the inclusion and exclusion criteria and are scheduled to undergo internal fixation surgery from the emergency and inpatient wards of multiple hospitals. General and disease-related data will be collected. All eligible patients must voluntarily sign an informed consent form after understanding and accepting the study. Successfully recruited participants will undergo internal fixation surgery at a scheduled time and then be randomly assigned to either the Venostan (horse chestnut seed extract tablet) group or the conventional treatment group. They will receive the corresponding treatments according to the study protocol. Follow-up assessments will include changes in ankle circumference, ankle range of motion, scale evaluation results, laboratory test results, and adverse events. The study aims to evaluate the effects of Venostasin in patients with ankle fractures undergoing internal fixation surgery, exploring its potential to promote postoperative reduction of ankle swelling, enhance early joint function recovery, and investigate its safety in postoperative fracture management.",[227],"Swelling\u002F Edema",[229,230,231,232,233,234],"Ankle fracture","Edema","Postoperative rehabilitation","horse chestnut seed extract","venostan","enhanced recovery after surgery","2025-07-14",{"date":237,"type":34},"2025-07-16",{"date":239,"type":34},"2025-04-16",{"date":241,"type":21},"2026-01-12",{"name":40,"class":41},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":263,"leadSponsor":264,"locationsCount":4},"100574261","long-term-outcomes-of-different-surgical-techniques-for-sacral-tarlov-cysts-a-prospective-cohort-study-100574261","NCT06756984","Long-Term Outcomes of Different Surgical Techniques for Sacral Tarlov Cysts: A Prospective Cohort Study","A Prospective Cohort Study on the Long-Term Outcomes and Prognostic Factors of Different Surgical Techniques for the Treatment of Sacral Tarlov Cysts","Inclusion Criteria\n\n1. Age 18-75 years.\n2. Diagnosed with symptomatic sacral Tarlov cysts confirmed by MRI.\n3. Presence of at least one of the following symptoms:\n\n   * Persistent sacral or lower back pain (VAS score ≥ 4).\n   * Neurological deficits such as lower extremity numbness or weakness.\n   * Bowel, bladder, or sexual dysfunction attributable to the cyst.\n4. Eligible for surgical intervention based on clinical evaluation.\n5. Willing and able to provide written informed consent.\n\nExclusion Criteria\n\n1. History of prior sacral Tarlov cyst surgery.\n2. Concurrent spinal conditions requiring separate surgical intervention.\n3. Active infection or systemic inflammatory disease.\n4. Severe comorbidities that increase surgical risk (e.g., advanced cardiac or pulmonary disease).\n5. Pregnancy or lactation.\n6. Inability to comply with follow-up requirements.\n7. Known allergy or contraindication to surgical materials (e.g., fibrin glue).","75 Years",{"count":252,"type":21},150,"Brief Summary\n\nThe goal of this observational study is to evaluate the long-term outcomes of different surgical techniques for sacral Tarlov cysts in adult patients aged 18-75 years diagnosed with symptomatic sacral Tarlov cysts. The main questions it aims to answer are:\n\n* Does one surgical technique result in better pain relief (measured by VAS score) and functional recovery (measured by JOA score) compared to others?\n* How do different surgical techniques impact the long-term recurrence rate and complication rate?\n\nResearchers will compare three surgical techniques:\n\n1. Partial cyst wall resection with nerve root sleeve plasty.\n2. Partial cyst wall resection with nerve root sleeve reinforcement and reconstruction.\n3. Autologous fat\u002Fmuscle with fibrin glue microscopic cyst filling.\n\nParticipants will:\n\n* Undergo one of the three surgical procedures based on clinical indications.\n* Complete preoperative and postoperative assessments, including pain and functional scoring, as well as MRI evaluations at baseline and during follow-up.\n* Participate in a follow-up program for up to 2 years to monitor outcomes and recurrence.",[255,256,257,258],"Sacral Tarlov Cysts","Symptomatic Sacral Cysts","Chronic Pain Related to Sacral Cysts","Neurological Dysfunction Associated With Tarlov Cysts","2025-05-12",{"date":261,"type":34},"2025-05-13",{"date":261,"type":21},{"date":185,"type":21},{"name":40,"class":41},""]